Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

Asia’s leading multi-asset exchange

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Equity Bottom-Up

<h2>10 Questions for Cordlife Group Limited</h2>
Company Overview Established in May 2001, Cordlife Group is a leading company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord lood banking in Asia. <a href="https://www.sgx.com/securities/equities/P8A" target="_blank" rel="noopener">Link to StockFacts company page</a>
<ol>
<li>Could you elaborate on Cordlife’s business segments and each of its focus?</li>
</ol>
<ul>
<li>We are a pioneer in private cord blood banking and own the largest network of cord blood banks in Asia with full stem cell banking facilities in 6 key markets – Singapore, Hong Kong, Indonesia, India, Malaysia, and the Philippines. All our facilities are accredited by <a href="http://www.aabb.org/?force_isolation=true" target="_blank" rel="noopener">AABB</a> (formerly known as American Association of Blood Banks), with several also accredited by other leading standards organisations, such as Foundation for the Accreditation of Cellular Therapy (<a href="http://www.factwebsite.org/?force_isolation=true" target="_blank" rel="noopener">FACT</a>) and College of American Pathologists (CAP).</li>
<li>Beyond cord blood, cord lining and cord tissue banking, we have extended our cryopreservation expertise to expanded stem cells in the Philippines and lenticules in Singapore, offering a comprehensive suite of diagnostics services for families including non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening and family genetic screening services.</li>
<li>We recently introduced the digital healthcare business segment and developed Moms Up, a mobile app, to provide health-related information and resources for Asian women who are expecting or planning to conceive, and women who have young children. Moms Up is available in the Philippines, Indonesia and Malaysia and will be made available soon in all our markets.</li>
</ul>
2. Cordlife operates in 6 key markets, are there plans to expand the Group’s geographical reach?
<ul>
<li>In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and we are amongst the top 3 market leaders in India and Malaysia. Through our majority-owned subsidiary in Malaysia, Stemlife Berhad, we own an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife has also established a presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh.</li>
<li>While we have managed to establish our position in Asia, we are also looking to strengthen our market position and expand our footprint beyond the current markets. We aim to deepen the penetration of our banking services in each market and increase revenue contribution from the diagnostic and digital healthcare business segments.</li>
</ul>

10 Questions for Cordlife Group Limited
Company Overview Established in May 2001, Cordlife Group is a leading company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord lood banking in Asia. Link to StockFacts company page

Could you elaborate on Cordlife’s business segments and each of its focus?


We are a pioneer in private cord blood banking and own the largest network of cord blood banks in Asia with full stem cell banking facilities in 6 key markets – Singapore, Hong Kong, Indonesia, India, Malaysia, and the Philippines. All our facilities are accredited by AABB (formerly known as American Association of Blood Banks), with several also accredited by other leading standards organisations, such as Foundation for the Accreditation of Cellular Therapy (FACT) and College of American Pathologists (CAP).
Beyond cord blood, cord lining and cord tissue banking, we have extended our cryopreservation expertise to expanded stem cells in the Philippines and lenticules in Singapore, offering a comprehensive suite of diagnostics services for families including non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening and family genetic screening services.
We recently introduced the digital healthcare business segment and developed Moms Up, a mobile app, to provide health-related information and resources for Asian women who are expecting or planning to conceive, and women who have young children. Moms Up is available in the Philippines, Indonesia and Malaysia and will be made available soon in all our markets.

2. Cordlife operates in 6 key markets, are there plans to expand the Group’s geographical reach?

In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and we are amongst the top 3 market leaders in India and Malaysia. Through our majority-owned subsidiary in Malaysia, Stemlife Berhad, we own an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife has also established a presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh.
While we have managed to establish our position in Asia, we are also looking to strengthen our market position and expand our footprint beyond the current markets. We aim to deepen the penetration of our banking services in each market and increase revenue contribution from the diagnostic and digital healthcare business segments.


10 in 10 with Cordlife Group - Being The One Choice For Parents